The Relevance Of ePROs In Early Phase Clinical Trials

Early phase clinical research, encompassing phases 1 and 2a, serves as the cornerstone for understanding the behavior of investigational products in humans and determining optimal dosages and safety profiles. However, the integration of patient perspectives and electronic Patient Reported Outcomes (ePROs) into these phases is increasingly recognized as pivotal for both scientific advancement and market success. By embracing ePROs from the outset, clinical teams gain valuable insights into patient experiences, streamline trial design for later stages, and bolster the overall market value of their innovations.

Here, we delve into how early adoption of ePROs not only refines clinical development strategies but also cultivates a deeper understanding of patient needs, ultimately reshaping the landscape of pharmaceutical innovation and market access.